Karyopharm Therapeutics Inc KPTI

US Biotechnology

$1.92 ▼ -72.61% ($-5.09)

🧊 52W Low ⬇️ Below Yest. Low 🔥 High Short Interest 🗓️ Earnings Next Week

Open $2.19

Prev Close $7.01

Day Range $1.80 – $2.43

52W Range $1.80 – $10.99

Market Cap $158.87M

Beta 0.94

EPS (TTM) $-14.84

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2013-11-06
Shares Out.	22,660,000
Website	karyopharm.com/ ↗
Phone	13026587581
Employees	228
Revenue	$35.1M
Gross Profit	$33.7M
Net Income	-$22.4M
Total Assets	$131.4M
Total Liabilities	$397.1M
Equity	-$265.6M

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Karyopharm Therapeutics Inc is a publicly traded company under the ticker symbol KPTI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.